Loading…

Pall Corporation was selected by Servier as the exclusive technology and services provider for Servier's new biomanufacturing facility in Gidy, France. Pall will provide end-to-end biomanufacturing solutions for monoclonal antibodies and recombinant proteins. The Bio-S project includes up to 2,000L bioreactor capacity, with the Bio-engineering unit operational by 2019 and the rest by 2020.
“Pall was chosen as a single vendor for our unique ability to offer integrated solutions that help to guarantee supply chain security for customers and patients.”biospace.com
Summarized from public sources; check the original articles before acting on it.